<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="444">
  <stage>Registered</stage>
  <submitdate>7/04/2004</submitdate>
  <approvaldate>7/04/2004</approvaldate>
  <nctid>NCT00081068</nctid>
  <trial_identification>
    <studytitle>Alemtuzumab in Treating Patients With Waldenstrom's Macroglobulinemia</studytitle>
    <scientifictitle>Phase II Study of Campath-1H in Lymphoplasmacytic Lymphoma (Waldenstrom's Macroglobulinemia)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>UCLA-0309058</secondaryid>
    <secondaryid>CDR0000358811</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Lymphoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Children's - Leukaemia &amp; Lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - alemtuzumab

Other interventions: alemtuzumab


</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Objective response</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Time to treatment failure</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Toxicity</outcome>
      <timepoint />
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>DISEASE CHARACTERISTICS:

          -  Diagnosis of Waldenstrom's macroglobulinemia (lymphoplasmacytic lymphoma)

               -  Immunoglobulin (Ig) M, IgG, and IgA paraprotein

               -  Measurable monoclonal paraprotein

          -  Failed at least 1 prior first-line therapy (alkylator agent, nucleoside analogue, or
             rituximab)

          -  CD52-positive tumor determined by either bone marrow immunohistochemistry or flow
             cytometry

        PATIENT CHARACTERISTICS:

        Age

          -  Over 18

        Performance status

          -  ECOG 0-2

        Life expectancy

          -  At least 6 months

        Hematopoietic

          -  Absolute neutrophil count = 500/mm^3

          -  Platelet count = 25,000/mm^3

        Hepatic

          -  SGOT = 2.5 times upper limit of normal (ULN)

          -  Bilirubin = 2.5 times ULN

        Renal

          -  Creatinine = 2.5 mg/dL (&gt; 2.5 mg/dL allowed if due to disease)

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective double-method contraception during and for 6
             months after study participation

          -  No serious comorbid disease

          -  No uncontrolled bacterial, fungal, or viral infection

          -  No other active malignancy

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  See Disease Characteristics

          -  No prior alemtuzumab

          -  More than 3 months since other prior monoclonal antibody therapy

        Chemotherapy

          -  See Disease Characteristics

          -  More than 21 days since prior chemotherapy

        Endocrine therapy

          -  More than 21 days since prior steroid therapy

        Radiotherapy

          -  More than 21 days since prior radiotherapy

        Surgery

          -  Not specified</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/01/2004</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>0</actualsamplesize>
    <recruitmentstatus>Withdrawn</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Peter MacCallum Cancer Centre - East Melbourne</hospital>
    <postcode>3002 - East Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lens</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>England</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Jonsson Comprehensive Cancer Center</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Government body</othercollaboratortype>
      <othercollaboratorname>National Cancer Institute (NCI)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>RATIONALE: Monoclonal antibodies, such as alemtuzumab, can locate tumor cells and either kill
      them or deliver tumor-killing substances to them without harming normal cells.

      PURPOSE: This phase II trial is studying how well alemtuzumab works in treating patients with
      Waldenstrom's macroglobulinemia.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00081068</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Jennifer Gansert, MD, PhD</name>
      <address>Jonsson Comprehensive Cancer Center</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>